||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Datenschutz
Impressum
Bankleitzahlen - online.de


Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis

Novartis International AG /
Novartis presents data to advance understanding of the role of IL-17A and
reinforce Cosentyx® leadership in spondyloarthritis
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.


* 26 abstracts on Cosentyx(®) (secukinumab) in ankylosing spondylitis (AS) and
psoriatic arthritis (PsA) will be presented at the Annual European Congress
of Rheumatology (EULAR 2018)[1]

* Breadth of data covers updates on radiographic progression, quality of life
and real-world evidence of patient satisfaction with Cosentyx - including 9
abstracts on AS, putting Novartis at the forefront of driving scientific
understanding of this debilitating disease[1]

* Cosentyx specifically inhibits IL-17A, a cornerstone cytokine involved in
the development of AS and PsA[2]-[6]. To date, Cosentyx has been prescribed
to more than 150,000 patients to worldwide[7]

Basel, June 13, 2018 - Novartis will attend the Annual European Congress of
Rheumatology (EULAR 2018) with 26 accepted abstracts reinforcing the roles of
Cosentyx(®) (secukinumab) and IL-17A, cornerstone cytokine in the development of
ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1]. EULAR 2018 will be
taking place June 13-16, in Amsterdam, Netherlands.

"For patients living with PsA and AS it is crucial to have therapy options that
could help slow down the disease and maintain mobility," said Professor Robert
Landewé, Professor of Rheumatology, Academic Medical Centre, Amsterdam, the
Netherlands. "The strong data flow on IL-17A at EULAR enhances scientific
understanding and advances knowledge on how to best manage these progressive and
painful diseases."

"I would like to thank the patients who participated in our trials as well as
the investigators and sites who worked with us to run the studies being
presented at EULAR 2018," said Eric Hughes, Global Development Unit Head,
Immunology, Hepatology and Dermatology. "Collaboration is a key component in
driving scientific understanding of spondyloarthritis forward, broadening
treatment options for clinicians and, ultimately, improving patient outcomes."

Abstracts accepted at EULAR 2018 include new radiographic progression data in AS
and PsA, as well as real-world evidence of patient satisfaction with
Cosentyx[1].

Inhibition of radiographic progression in PsA
FUTURE 5 radiographic data show Cosentyx inhibits progression of psoriatic
arthritis (PsA) out to Week 24[8]. Radiographic progression in PsA may lead to
mobility loss, and even to disability, a major patient concern[9]. (Abstract:
Van der Heijde D et al., Subcutaneous secukinumab inhibits radiographic
progression in psoriatic arthritis: analysis by prior anti-TNF therapy and
concomitant methotrexate use.) Link

No radiographic progression in AS
Data from MEASURE 1 show almost 80% of ankylosing spondylitis (AS) patients on
Cosentyx have no radiographic progression of the spine at 4 years[10].
(Abstract: Baraliakos X et al., Secukinumab demonstrates low radiographic
progression and sustained efficacy through 4 years in patients with active
ankylosing spondylitis.) Link

Patient satisfaction with Cosentyx in AS
Real-world evidence shows that over 90% of AS patients who were treated with
Cosentyx for 3 months or more were satisfied with their overall symptom
improvement and most patients (74%) indicated overall symptom improvement to be
better with Cosentyx compared to their previous treatment[11]. (Abstract: Magrey
M et al. Treatment experience and satisfaction in ankylosing spondylitis
patients treated with secukinumab: results from a US web-based survey.) Link

Sustainable efficacy and safety with Cosentyx through 4 years in AS
Data from MEASURE 2 study demonstrate Cosentyx provides sustained improvement in
signs and symptoms of AS through 4 years with a consistent and favorable safety
profile[12]. (Abstract: Marzo-Ortega H et al. Secukinumab 150 mg provides
sustained improvements in the signs and symptoms of active ankylosing
spondylitis with high retention rate: 4-year results from the Phase III trial,
MEASURE 2.) Link

About Cosentyx (secukinumab)
Cosentyx is the first fully-human biologic that specifically inhibits IL-17A, a
cornerstone cytokine involved in the inflammation and development of AS, PsA and
psoriasis[2]-[6]. IL-17A is produced by various cells from both the innate
immune system (which can be triggered by mechanical stress) and the adaptive
immune system[6]. By acting directly on IL-17A, Cosentyx inhibits the disease
irrespective of the source of IL-17A.

These data add to a growing body of evidence showing the unique position of
Cosentyx with long-lasting efficacy and a proven safety profile to treat AS, PsA
and moderate-to-severe psoriasis[13]-[16]. To date, Cosentyx has been prescribed
to more than 150,000 patients worldwide[7].

Disclaimer
This press release contains forward-looking statements within the meaning of the
United States Private Securities Litigation Reform Act of 1995. Forward-looking
statements can generally be identified by words such as "potential," "can,"
"will," "plan," "expect," "anticipate," "look forward," "believe," "committed,"
"investigational," "pipeline," "launch," or similar terms, or by express or
implied discussions regarding potential marketing approvals, new indications or
labeling for the investigational or approved products described in this press
release, or regarding potential future revenues from such products. You should
not place undue reliance on these statements. Such forward-looking statements
are based on our current beliefs and expectations regarding future events, and
are subject to significant known and unknown risks and uncertainties. Should one
or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those set
forth in the forward-looking statements. There can be no guarantee that the
investigational or approved products described in this press release will be
submitted or approved for sale or for any additional indications or labeling in
any market, or at any particular time. Nor can there be any guarantee that such
products will be commercially successful in the future. In particular, our
expectations regarding such products could be affected by, among other things,
the uncertainties inherent in research and development, including clinical trial
results and additional analysis of existing clinical data; regulatory actions or
delays or government regulation generally; global trends toward health care cost
containment, including government, payor and general public pricing and
reimbursement pressures; our ability to obtain or maintain proprietary
intellectual property protection; the particular prescribing preferences of
physicians and patients; general political and economic conditions; safety,
quality or manufacturing issues; potential or actual data security and data
privacy breaches, or disruptions of our information technology systems, and
other risks and factors referred to in Novartis AG's current Form 20-F on file
with the US Securities and Exchange Commission. Novartis is providing the
information in this press release as of this date and does not undertake any
obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2017, the Group achieved
net sales of USD 49.1 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
124,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please visit
http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations@novartis.com

References
    [1]    The Annual European Congress of Rheumatology - List of Accepted
Abstracts. Available at: https://b-com.mci-
group.com/AbstractList/EULAR2018.aspx. Last accessed June 2018.
    [2]    Cosentyx Summary of Product Characteristics. Novartis Europharm
Limited. Available at:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/0037
29/human_med_001832.jsp&mid=WC0b01ac058001d124. Last accessed June 2018.
    [3]    Smith JA et al. Review: The Interleukin 23/Interleukin 17 Axis in
Spondyloarthritis Pathogenesis: Th17 and Beyond. Arthritis Rheumatol
2014; 66: 231-41.
    [4]    Nestle FO et al. Mechanisms of disease psoriasis. N Eng J Med
2009; 361: 496-509.
    [5]    Girolomoni G et al. Psoriasis: rationale for targeting interleukin-
17. Br J Dermatol 2012; 167: 717-24.
    [6]    Schett G et al. Enthesitis: from pathophysiology to treatment. Nat
Rev Rheumatol 2017 ;13(12): 731-741.
    [7]    Novartis. Data on file.
    [8]    Van der Heijde D et al. Subcutaneous secukinumab inhibits
radiographic progression in psoriatic arthritis: analysis by prior anti-TNF
therapy and concomitant methotrexate use. Abstract presented at the EULAR 2018
Annual Meeting, Amsterdam, Netherlands. 15 June 2018.
    [9]    Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the
diagnosis and pharmacologic treatment of psoriatic arthritis in patients with
psoriasis. Drugs 2014; 74: 423-441.
    [10]  Baraliakos X et al. Secukinumab demonstrates low radiographic
progression and sustained efficacy through 4 years in patients with active
ankylosing spondylitis. Abstract presented at the EULAR 2018 Annual Meeting,
Amsterdam, Netherlands. 16 June 2018.
    [11]  Magrey M et al. Treatment experience and satisfaction in ankylosing
spondylitis patients treated with secukinumab: results from a US web-based
survey. Abstract presented at the EULAR 2018 Annual Meeting, Amsterdam,
Netherlands. 16 June 2018.
    [12]  Marzo-Ortega H et al. Secukinumab 150 mg provides sustained
improvements in the signs and symptoms of active ankylosing spondylitis with
high retention rate: 4-year results from the Phase III trial, MEASURE 2.
Abstract presented at the EULAR 2018 Annual Meeting, Amsterdam, Netherlands. 16
June 2018.
    [13]  Bissonnette R et al. Secukinumab Demonstrates High Sustained Efficacy
and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis
through 5 Years of Treatment (SCULPTURE Extension Study). J Eur Acad Dermatol
Venereol. ePub ahead of print. doi:10.1111/jdv.14878.
    [14]  Reich K et al. Secukinumab, a fully human anti-interleukin-17A
monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-
to-severe plaque psoriasis. Br J Dermatol. 2017; 176: 752-58.
    [15]  Mease PJet al. Secukinumab provides sustained improvements in the
signs and symptoms of active psoriatic arthritis through 3 years: efficacy and
safety results from a phase 3 trial. Ann Rheum Dis. 2017; 76: 952-953.
    [16]  Braun J et al. Secukinumab demonstrates low radiographic progression
and sustained efficacy through 4 years in patients with active ankylosing
spondylitis. Late breaking abstract presented at the 2017 ACR/ARHP Annual
Meeting, San Diego, USA. 7th November 2017.

# # #

Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com

Eric Althoff Friedrich von Heyl
Novartis Global Media Relations Novartis Global Pharma Communications
+41 61 324 7999 (direct) +41 61 324 8984 (direct)
+41 79 593 4202 (mobile) +41 79 749 0286 (mobile)
eric.althoff@novartis.com friedrich.vonheyl@novartis.com


Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central   North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188



Media release (PDF):
http://hugin.info/134323/R/2198937/852583.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novartis International AG via GlobeNewswire



 
 ||| Themen-Infos 
· Mehr zu dem Thema Allgemeine Nachrichten

Der meistgelesene Artikel zu dem Thema Allgemeine Nachrichten:
FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.087 Sekunden